accueil

Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Based in Paris, France, with offices in London and Milan, the firm brings together a team of over 40 professionals from all over Europe, the U.S., and Asia. 

The firm focuses on paradigm-shifting technologies alongside visionary entrepreneurs. Sofinnova Partners invests across the Life Sciences value chain as a lead or cornerstone investor, from very early-stage opportunities to late-stage/public companies. It has backed over 500 companies over five decades, creating market leaders around the globe. Today, Sofinnova Partners has over €2 billion under management.

Sofinnova Partners invest in start-ups, early-stage companies, corporate spin-offs, and occasionally turnaround situations. The firm invests in Life Sciences (Biopharmaceuticals / Biotech, Medical Devices, Industrial Biotechnology). Sofinnova Partners proactively sources deals, takes a lead role, is most often the first institutional investor in Round A financings, and leads its portfolio companies until exit. The firm's partners sit on the boards of its portfolio companies and play an active role in the formation phase alongside entrepreneurs. Sofinnova Partners invests throughout Europe from its headquarters in Paris with a portion of investments made in the rest of the world.

View More

Seasoned Medical Executive to Commercialize CorVent's RESPOND-19™ Ventilator

Serial entrepreneur brings exceptional experience from a range of leadership roles   Italy, Milan, 30 July 2020: Genespire, a gene therapy company developing transformative therapies for genetic diseases, today announces the appointment of Jörn Aldag as Chairm...

Casdin Capital leads the $50M extension; funding will support commercial launch of SYNTAX™ the world’s first enzymatic DNA printer. July 29, 2020 03:00 AM Eastern Daylight Time PARIS & SOUTH SAN FRANCISCO--(BUSINESS WIRE)--DNA Script today announced a $50 mill...

Financing co-led by seed investor Sofinnova Partners and incoming investor AbbVie, with additional investment from JDRF T1D Fund and several Italian investors   Largest international VC-backed Series A financing round for biotech in Italy to date and first eve...

Inotrem’s clinical study on Covid-19 was selected by the French government to be part of its €78 M action plan aimed at reinforcing the countries’ research capabilities for therapeutic solutions.   Pre-clinical studies have demonstrated nangibotide’s capacity ...

Gérard Hascoët

Gérard Hascoët

Venture Partner

MEET OUR TEAM